Strategy for molecular testing in pulmonary carcinoma

Annales de pathologie
Frédérique Penault-LlorcaAnne Cayre

Abstract

Nowadays, the analysis of theranostic molecular markers is central in the management of lung cancer. As those tumors are diagnosed in two third of the cases at an advanced stage, molecular screening is frequently performed on "small samples". The screening strategy starts by an accurate histopathological characterization, including on biopsies or cytological specimens. WHO 2015 provided a new classification for small biopsy and cytology, defining categories such as non-small cell carcinoma (NSCC), favor adenocarcinoma (TTF1 positive), or favor squamous cell carcinoma (p40 positive). Only the NSCC tumors, non-squamous, are eligible to molecular testing. A strategy aiming at tissue sparing for the small biopsies has to be organized. Tests corresponding to available drugs are prioritized. Blank slides will be prepared for immunohistochemistry and in situ hybridization based tests such as ALK. DNA will then be extracted for the other tests, EGFR mutation screening first associated or not to KRAS. Then, the emerging biomarkers (HER2, ROS1, RET, BRAF…) as well as potentially other markers in case of clinical trials, can been tested. The spread of next generation sequencing technologies, with a very sensitive all-in-one approach will ...Continue Reading

References

Feb 3, 2006·The New England Journal of Medicine·Antonio MarchettiFiamma Buttitta
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Dec 2, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Giorgio ScagliottiChandra P Belani
Apr 26, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Aude LamyJean-Christophe Sabourin
Nov 11, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Anne McLeer-FlorinSylvie Lantuejoul
Feb 14, 2012·Nature Medicine·Kengo TakeuchiYuichi Ishikawa
Jul 11, 2012·Nature Reviews. Clinical Oncology·Frédérique NowakFabien Calvo
Jul 25, 2012·Virchows Archiv : an International Journal of Pathology·Erik ThunnissenGiulio Rossi
Oct 17, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Leow Pay ChinSai-Hong I Ou
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alice T Shaw, Jeffrey A Engelman
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Geoffrey R OxnardPasi A Jänne
Apr 9, 2013·The Journal of Molecular Diagnostics : JMD·Neal I Lindeman College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathol
May 30, 2013·American Society of Clinical Oncology Educational Book·Frédérique NowakJean-Charles Soria
Dec 18, 2013·Seminars in Diagnostic Pathology·Giulio RossiRaffaele Califano
Mar 19, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yunjian PanHaiquan Chen
Sep 26, 2014·Archives of Pathology & Laboratory Medicine·Lynette M Sholl
Jan 21, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Nataliya MarJeffrey S Wasser
May 2, 2015·The European Respiratory Journal·Sylvie LantuejoulAnne McLeer-Florin
Aug 1, 2015·American Journal of Respiratory and Critical Care Medicine·Avrum SpiraCharles A Powell

❮ Previous
Next ❯

Citations

Aug 8, 2018·Cancer Chemotherapy and Pharmacology·Lixia JuZhengwei Dong
Mar 11, 2020·The Pan African Medical Journal·Karam Yahya BelmokhtarLoubna Mezouar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.